Clemence Cleave RNutr’s Post

The research also suggests that people who are taking lipid-lowering drugs such as statins to lower their cholesterol levels should remain on them, even if their cholesterol levels have fallen, as stopping treatment could increase their risk of atherosclerosis. Atherosclerosis is one of the major causes of heart and circulatory disease. It involves the hardening […] https://lnkd.in/dmTbKHPc www.Cyprus-CEO.com #CEO #business #management #marketing #tech #AI #legal #money

The research also suggests that people who are taking lipid-lowering drugs such as statins to lower their cholesterol levels should remain on them, even if their cholesterol levels have fallen, as stopping treatment could increase their risk of atherosclerosis. Atherosclerosis is one of the major causes of heart and circulatory disease. It involves the hardening […] https://lnkd.in/dmTbKHPc www.Cyprus-CEO.com #CEO #business #management #marketing #tech #AI #legal #money

Excellent news. Thanks again science! 🔬😊 Weight loss jab 'could reduce heart attack risk', BBC https://lnkd.in/dCHa-Mb3 #preventative #health #obesity By preventing harm before it happens this improves lives, reduces demand for overstretched health services and saves money. Win, win, win! "the drug makes people feel fuller and more satisfied, so they eat less" "An injection designed to tackle obesity could reduce the risk of heart attacks and strokes in people regardless of the amount of weight they lose while on the drug, according to a new study. Researchers looked at the effects of semaglutide - which is a prescription drug that supresses appetite and is sold under the brand names Wegovy, Ozempic and Rybelsus. They said the anti-obesity jabs could also benefit the cardiovascular health of millions of adults. Prof John Deanfield CBE, who led the team of researchers, said the generic drug could have a positive impact on blood sugar, blood pressure or inflammation, as well as direct effects on the heart muscle and vessels." UCL "After 20 weeks of being on semaglutide, 62% of patients had lost more than 5% of their bodyweight compared with 10% in a placebo group. However, the risk reduction of heart attacks, stroke or heart failure was similar in patients who lost more than 5% of their bodyweight and in those who lost less than 5%, or gained weight." "second [study], led by Prof Donna Ryan, of Pennington Biomedical Research Center in New Orleans, looked at the long-term effect of semaglutide on weight." "experts have previously warned it is not a quick fix or a replacement for eating well and exercising, and should only be offered under medical supervision." Thomas Mackintosh

A recent study has revealed that rilmenidine, a drug commonly prescribed for hypertension, may hold the key to extending lifespan and slowing down the aging process. The research demonstrated that rilmenidine mimics the effects of caloric restriction, a proven anti-aging intervention. https://lnkd.in/gYDYBSAf FuturistSpeaker.com #foresight #predictions #futuretrends #futureofwork #futurejobs #keynotespeaker #futuriststrategy #mostquoted

I worked in academia for ~15 years studying multiple aspects of obesity (epidemiological, biological, molecular) and its relationship to chronic illness and let me tell you, the evidence is overwhelming. However, despite thousands of published, peer-reviewed studies, the eat less/exercise more admonishment approach has failed to slow the fattening of our planet. While the history of weight-loss drugs has been fraught, there is a new wave of highly effective biologics that mimic the beneficial aspects of diet/exercise at the molecular level. While obesity is a complex disease, it is fundamentally rooted in a disconnect between our thrifty genetics and the built environment. Furthermore, obesity and its associated health effects disproportionately affect low-income individuals who have limited access to ($$, time and facilities) healthy food and effective exercise. Universal access to weight-loss drugs such as GLP-1RAs will not ameliorate these health disparities but they will level the playing field, which is a start. To get there we need to dramatically reduce the cost and increase the accessibility of these drugs for lower-income individuals. At Cadence Bioworks one of our first projects will be to develop proof-of-concept low cost alternatives to GLP-1RA drugs by combining revolutiuonary advances in RNA technology with the innate capacity of skeletal muscle to produce and secrete proteins into the blood. If successful, this platform could develop into much, much more…..stay tuned.  

We are pleased to share new and updated clinical documents that our stakeholders have recently released: 📄 Periprocedural use of GLP-1/GIP receptor agonists: This document provides consensus recommendations for managing the periprocedural use of GLP-1RAs and GLP-1/GIPRAs, with a focus on mitigating risks such as pulmonary aspiration: https://ow.ly/PAoH50TcaNE 📄 FDG PET/CT imaging in diabetes: Guidance about preparing and managing people living with diabetes for PET/CT imaging, covering essential protocols such as fasting and insulin management: https://ow.ly/EF4Z50TcaNG 📄 Australian obesity management algorithm: A tool for primary care clinicians, integrating the latest evidence to enhance decision-making in obesity management: https://ow.ly/mp7m50TcaNM 📄 Updated Australian type 2 diabetes glycaemic management algorithm: A vital resource for improving glycaemic management in people living with type 2 diabetes: https://ow.ly/8VOG50TcaNy These resources are now available on the ADEA website: https://ow.ly/S3Si50TcaNC

Obesity: Disease or Lack of Willpower? 9/24/24 Ozempic/Wegovy/Zepbound/Mounjaro will unquestioningly become the best selling drugs ever. Not only do they lower blood sugar and improve diabetic control, but they also lead to bariatric surgery-type weight loss, reduce cardiovascular events in people with obesity (with and without diabetes), and early data suggests a favorable benefit for sleep apnea and addiction disorders (alcohol, smoking, gambling)….and are even receiving much attention in oncology circles as well. To the surprise of many, however, the medical field has failed to define what exactly constitutes obesity - and continue to simply diagnose it purely based on BMI. But this is a very poor tool that does not address the reality and nuance of the condition. It is time to strictly redefine “obesity”. It has tremendous medical, social and economical implications. The best piece I have read on this topic…. 👇

"New weight loss drugs have proven their effectiveness. Now researchers want to know how to best use them" Expand your knowledge about the LightCOM (The Lighthouse Consortium on Obesity Management) project from this article. https://lnkd.in/ec4JzQxU

GLP-1 receptor agonists are considered one of the most powerful anti-obesity agents currently available, and are only the tip of the iceberg in regard to obesity research. Read the article to find out the direction obesity drug research is heading, and the challenges faced by researchers. https://ow.ly/b2KA50RJFQ1

Choosing Between Ozempic and Other Weight Loss Drugs Patients now have a choice among drugs like Wegovy, Ozempic, Zepbound, and Mounjaro for obesity treatment. - Semaglutide, sold as Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro, are the primary options. - A recent study showed people lost more weight on Mounjaro compared to Ozempic. - Despite the promising results, experts caution that the studies are highly flawed. - Deciding on the best option remains complicated due to limitations in current research. 👍 https://lnkd.in/dNDMTTf3